Cellscript
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cellscript - overview
Established
2007
Location
Madison, WI, US
Primary Industry
Biotechnology
About
Cellscript is a biotechnology firm specializing in advanced mRNA technologies for clinical research and immunotherapy applications, focusing on synthesizing functional mRNAs with reduced immunogenicity using innovative techniques. Founded in 2007, Cellscript is based in Madison, US, and develops advanced mRNA technology solutions. The company was founded to address the challenges of mRNA design and synthesis for therapeutic applications. Gary Dahl, the CEO, has a background in the biotechnology sector but no information on previous ventures is provided.
Cellscript specializes in advanced mRNA technologies designed for clinical research and immunotherapy applications. Their core product offerings include functional mRNAs and innovative systems such as INCOGNITO™ T7 mScript™ and ScriptCap™ for post-transcriptional capping. These technologies aim to create mRNAs with reduced immunogenicity for enhanced performance in mammalian cells, serving a clientele that includes academic institutions, biotech firms, and pharmaceutical manufacturers in North America, Europe, and parts of Asia, focusing on gene therapy and vaccine development. Cellscript's revenue model is based on B2B transactions, selling products directly to research institutions and commercial entities within the biotechnology and pharmaceutical sectors.
They offer various mRNA synthesis tools, including the INCOGNITO™ T7 mScript™ and A-Plus™ Poly(A) Tailing Kit, with pricing plans tailored to client needs and order sizes. The business structure accommodates bulk purchasing to streamline the procurement process for high-volume clients.
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Website
www.cellscript.com
Total Amount Raised
Subscriber access only
Cellscript - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.